Skip to main content

ARGOS - A phase IV, prospective, 18-month study to assess the effectiveness and safety of bimatoprost intracameral implant (DURYSTA) in US clinical practice

Clinical Trial Grant
Duke Scholars

Administered By

Ophthalmology, Glaucoma

Awarded By

Allergan, Inc.

Start Date

November 1, 2021

End Date

May 1, 2024
 

Administered By

Ophthalmology, Glaucoma

Awarded By

Allergan, Inc.

Start Date

November 1, 2021

End Date

May 1, 2024